“…To compare, a heparin pentasaccharide (fondaparinux) bearing an IdoA moiety, exhibited significantly higher activity against FXa (IC 50 = 11.0 ± 0.1 nM) and limited activity against FIIa. 40 Next, we screened the ability of trisaccharide 1α to bind to the HS-binding protein, platelet factor-4 (PF4), which is responsible for causing thrombocytopenia, [42][43] the main reason why clinical trials for other carbohydrate-based heparanase inhibitors were halted. [44][45] To achieve this goal, a solution-based biolayer interferometry (BLI) assay was utilized to determine the apparent K d of compound 1α to PF4 in comparison to biotinylated-heparin (18 kDa) attached to the BLI streptavidin-probe.…”